Dr Naila Rabbani & Professor Paul Thornalley
Naila & Paul have over 50yrs of scientific experience between them with a career focused on understanding the finer elements of many different conditions. The ASD Protein Pattern™ test is the flagship test for iDiagnostix.
Dr Naila Rabbani BSc PhD – Founder & CEO
Naila Rabbani is a co-founder of iDiagnostix. With over 20 years experience in studying disease mechanisms and biomarkers. She is a driven research team leader of a multidisciplinary AGEomics and Systems Biology Research Group and is responsible for the development of blood tests with patented diagnostic algorithms for early detection of osteoarthritis, typing of arthritis and autism.
Utilising, developing and expanding the techniques of stable isotopic dilution analysis liquid chromatography-tandem mass spectrometry (LC-MS/MS) has enabled her to discover markers for both early detection and precision medicine.
Her research is focused on study of endogenous damage to proteins by glycation (modification by sugars), oxidation and nitration – and more recently citrullination – combining with artificial intelligence to develop diagnostic algorithms for early detection and where possible, prevention adverse outcomes. She is recognised internationally as one of the leaders in the field of advanced glycation endproducts (AGEs) in disease processes – particularly glycation of lipoproteins by methylglyoxal and risk of atherosclerosis and cardiovascular disease and diabetes.
The study of AGEs is a high profile area of biochemistry: AGEs are implicated in the development of chronic complications of diabetes, non-diabetic heart disease and kidney failure, and neurological disorders. She successfully led projects in the public and private sectors included validation of AGEs biomarkers in Nurses Health Study (NHS) and leading projects with Merck, Nestle, Unilever and others.
She has published over 130 peer-reviewed articles, over 140 conference papers and abstracts, and 8 patents which have received over 10,837 citations (h-index 58; Google Scholar)
Professor Paul J Thornalley BSc PhD – Founder & CSO
Paul is co-founder of iDiagnostix. He has over 37 years’ experience working in project management and dissemination as a biomedical research team leader, working in mechanisms of disease, translational medicine and drug discovery.
He led research on development of state-of-the-art techniques for quantitation of modification of proteins by glycation, oxidation and nitration – employing the technique of stable isotopic dilution analysis liquid chromatography-tandem mass spectrometry (LC-MS/MS). This has been applied to advanced research in neurological disorders and disease and continues to be the gold-standard methodology for analysis of other health impairments. This method is now employed in analytical laboratories worldwide.
He has experience in cell, pre-clinical in vivo and clinical studies and has led projects in the public and private sectors. The latter included leading projects with Merck, Nestle, Unilever and others.
He has published over 300 peer-reviewed articles, over 220 conference papers and 13 patents which have received over 30,400 citations (h-index 94; Google Scholar).
